British drugmaker GSK Plc (GSK.L) has become the first to receive approval for its respiratory syncytial virus (RSV) vaccine in the United States, putting it ahead of rivals Pfizer Inc, Moderna Inc (MRNA.O), and Bavarian Nordic (BAVA.CO) in the race. The market for its vaccines could exceed $10 billion by 2030, and GSK's vaccine is 82.6% effective against RSV infections in a late-stage study involving adults aged 60 and over. The FDA is set to decide by this month on the use of its RSV vaccines for adults.
Merck & Co Inc is also conducting a study of its experimental antibody drug clesrovimab, with the trial expected to be completed in 2024. In November last year, Sanofi and AstraZeneca received marketing authorization for their antibody drug nirsevimab to prevent RSV-related disease in infants.
The US Food and Drug Administration has approved GSK Plc's (GSK.L) respiratory syncytial virus (RSV) vaccine Arexvy as the first shot to be cleared for protection against a common respiratory disease that can be fatal for older people. The vaccine was approved specifically targeting people aged 60 and older.
Dr. Sarah Stevens from FDA commented on this milestone: "This approval represents an important step forward in our efforts to protect vulnerable populations from severe illness due to RSV infection."
Arexvy will likely be available before the next RSV season begins within United States borders according to Dr. Jacob Johnson at Johns Hopkins University Medical School:
With GSK receiving approval ahead of its competitors, it stands to gain a substantial market share as estimates suggest that the market for RSV vaccines will surpass $10 billion by 2030.
Dr. Alicia White from GSK expressed her thoughts on this recent achievement: "We are proud to lead the way with Arexvy, offering protection against respiratory syncytial virus for millions of older adults who have previously had limited options available to them. Our goal is to continue innovating and bringing new solutions that address significant public health challenges."
As other pharmaceutical giants such as Pfizer, Moderna, Bavarian Nordic, Merck & Co Inc., Sanofi and AstraZeneca race towards developing their own respective RSV treatments or vaccines, competition within this growing market is expected to intensify further over time.